Autopsy report · NCT03142191
A Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis
Cause of deathFunding or business
“Business objectives have changed.”
Life of this trial
- Registered 3 months before it started.
- Ran for about 4 years 5 months before it stopped.
- 138 participants enrolled.
- Results were posted on the registry 1 year 6 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Celgene
- Sponsor type
- Industry
- Conditions
- Idiopathic Pulmonary Fibrosis; Fibrosis; Idiopathic Interstitial Pneumonias; Pathologic Processes; Lung Diseases, Interstitial; Lung Diseases
- Interventions
- CC-90001; Placebo
- Participants
- 138
- Sites
- 112
- Countries
- Australia, Brazil, Canada, Colombia, Germany, Greece, Romania, Russia, Taiwan, Turkey (Türkiye), Ukraine, United Kingdom and more
Trials that died the same way
- Entecavir Plus Adefovir in Lamivudine-Resistant Patients
“Business Objectives Changed” - A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer
“Business objective has changed” - Phase I Ascending Multiple-Dose Study of BMS-986115 in Subjects With Advanced Solid Tumors
“(Non-safety reason, business objectives have changed)” - ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)
“Business strategy change” - A Prospective Study of the NUVANCE Facial Rejuvenation System for Mid-Face, Neck and Jowl Rejuvenation Procedures
“Change in business priorities.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.